Araris Biotech AG is at the forefront of developing innovative antibody-drug conjugate (ADC) technologies, specifically through its proprietary linker platform. This technology allows for the efficient attachment of drug payloads to standard antibodies in a single step, eliminating the need for complex re-engineering or reduction processes. The result is the creation of highly homogeneous, stable, and potent ADC therapies that can selectively deliver toxic drugs directly to cancer cells while minimizing damage to healthy tissues. The Araris Linker Technology is designed to maintain the original pharmacokinetics and effector functions of the antibodies, ensuring that they perform effectively even after conjugation.

The company addresses several critical challenges faced by existing ADC technologies, such as poor stability, high heterogeneity, and limited linker solubility. By utilizing a strong peptide bond for payload attachment and employing hydrophilic linkers, Araris ensures that its ADCs remain stable in bloodstream conditions, reducing the risk of aggregation and enhancing their ability to bind to cancer cells. This streamlined manufacturing process not only reduces costs and development time but also allows for the production of high-quality ADC candidates that have the potential to significantly improve therapeutic outcomes for cancer patients.

Switzerland

Araris Biotech AG is pioneering a novel linker technology for antibody-drug conjugates (ADCs.) Our linker platform enables the attachment of any payload to ‘off the shelf’ antibodies without the need of prior antibody engineering.

Araris Biotech

Company Details